Health Sciences Acquisitions Corporation 2
Status: Deal Closed
U=S
| IPO Proceeds, $M | $160.00M |
|---|---|
| IPO Date | Aug 4, 2020 |
| CEO | Roderick Wong, MD |
| Left Lead | Chardan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 3 + 1 + 1 + 1 |
| IPO Sector |
Healthcare
Biopharma and medical technology in North America or Europe |
| IPO Geography | Global |
| Target Company | Orchestra BioMed, Inc. |
| Deal Announced | Jul 5, 2022 |
| Deal Size, $M | $173.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Jan 24, 2023 |
| Amendment Vote | TBD |
| Closing Date | Jan 26, 2023 |
Formerly HSAQ
OBIO
| Price | $4.62 |
|---|---|
| Last closing price | $4.66 |
| H/L, today | $4.55 / $4.94 |
| H/L, 52-week | $4.26 / $23.39 |
| Volume, today | 16,272 |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Health Sciences Acquisitions Corporation 2:
- Structure and cap table
- 8 directors & officers
- 28 filings and events
- 3 underwriters
- 4 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Roderick Wong, MD | 43 | President, Chief Executive Officer and Chairman |
| Naveen Yalamanchi, MD | 43 | Executive Vice President, Chief Financial Officer and Director |
| Alice Lee, JD | 50 | Vice President of Operations, Secretary and Treasurer |
| Stephanie A. Sirota | 45 | Vice President of Corporate Strategy and Corporate Communications |
| Pedro Granadillo | 73 | Director |
| Carsten Boess | 54 | Director |
| Stuart Peltz, PHD | 60 | Director |
| Michael Brophy | 40 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Chardan | 8,297,826 | units | |
| Barclays | 5,565,218 | ||
| B. Riley FBR | 50,000 | ||
| 13,913,044 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.
Filings
Sign in to view 28 filings.